Research programme: osteoarthritis pain therapeutics - Calchan/Galapagos
Latest Information Update: 29 Oct 2014
At a glance
- Originator Calchan; Galapagos NV
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Musculoskeletal pain
Most Recent Events
- 27 Oct 2014 Early research in Musculoskeletal pain in Belgium (unspecified route)
- 27 Oct 2014 Early research in Musculoskeletal pain in United Kingdom (unspecified route)